CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

Milestone (WA: MMD )’s President and CEO, Joe Oliveto, expressed the company’s disappointment with the CRL but reaffirmed their commitment to CARDAMYST as a potential novel treatment for PSVT. The ...

Milestone Pharmaceuticals had $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024.

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...

Approximately 2 hours after admission atrial fibrillation, with an irregular ventricular response, was noted, the rate being as low as 34 per minute. She continued to be symptomatic; specifically ...

Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...

Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...

Milestone is also on track to initiate a Phase 3 trial for etripamil in patients with AFib-RVR in 2025. A recent investor event detailed the commercialization strategy for CARDAMYST. We have seen ...

Tricuspid regurgitation (TR) severity is associated with poor prognosis in patients with atrial fibrillation (AF). Recently, right ventricular–pulmonary arterial (RV‐PA) coupling has been shown to be ...